These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 36837928)

  • 21. Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model.
    Kiy RT; Khoo SH; Chadwick AE
    Toxicol Res (Camb); 2024 Feb; 13(1):tfae012. PubMed ID: 38328743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative docking and molecular dynamics studies of molnupiravir (EIDD-2801): implications for novel mechanisms of action on influenza and SARS-CoV-2 protein targets.
    Istifli ES; Okumus N; Sarikurkcu C; Kuhn ER; Netz PA; Tepe AS
    J Biomol Struct Dyn; 2024 Sep; 42(15):8202-8214. PubMed ID: 37811782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
    Waters MD; Warren S; Hughes C; Lewis P; Zhang F
    Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.
    Marikawa Y; Alarcon VB
    Reprod Toxicol; 2023 Oct; 121():108475. PubMed ID: 37748715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
    Menéndez-Arias L
    J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    bioRxiv; 2022 Feb; ():. PubMed ID: 35233571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
    Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
    J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
    Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody.
    Zibat A; Zhang X; Dickmanns A; Stegmann KM; Dobbelstein AW; Alachram H; Soliwoda R; Salinas G; Groß U; Görlich D; Kschischo M; Wollnik B; Dobbelstein M
    iScience; 2023 Oct; 26(10):107786. PubMed ID: 37731621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
    Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
    J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35579953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir?
    Clark NF; Taylor-Robinson AW; Heimann K
    Ther Adv Drug Saf; 2022; 13():20420986221107753. PubMed ID: 35898799
    [No Abstract]   [Full Text] [Related]  

  • 33. RdRp inhibitors and COVID-19: Is molnupiravir a good option?
    Hashemian SMR; Pourhanifeh MH; Hamblin MR; Shahrzad MK; Mirzaei H
    Biomed Pharmacother; 2022 Feb; 146():112517. PubMed ID: 34902743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
    Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
    Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.
    Tang W-F; Chang Y-H; Lin C-C; Jheng J-R; Hsieh C-F; Chin Y-F; Chang T-Y; Lee J-C; Liang P-H; Lin C-Y; Lin G-H; Cai J-Y; Chen Y-L; Chen Y-S; Tsai S-K; Liu P-C; Yang C-M; Shadbahr T; Tang J; Hsu Y-L; Huang C-H; Wang L-Y; Chen CC; Kau J-H; Hung Y-J; Lee H-Y; Wang W-C; Tsai H-P; Horng J-T
    Antimicrob Agents Chemother; 2024 Apr; 68(4):e0095623. PubMed ID: 38446062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the frequency of SARS-CoV-2 Omicron variant escape from RNA-dependent RNA polymerase inhibitors and 3C-like protease inhibitors.
    Takashita E; Fujisaki S; Morita H; Nagata S; Miura H; Nagashima M; Watanabe S; Takeda M; Kawaoka Y; Hasegawa H
    Antiviral Res; 2023 Aug; 216():105671. PubMed ID: 37451629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potent Dual Polymerase/Exonuclease Inhibitory Activities of Antioxidant Aminothiadiazoles Against the COVID-19 Omicron Virus: A Promising In Silico/In Vitro Repositioning Research Study.
    Rabie AM; Eltayb WA
    Mol Biotechnol; 2024 Apr; 66(4):592-611. PubMed ID: 36690820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative molecular docking and simulation analysis of molnupiravir and remdesivir with SARS-CoV-2 RNA dependent RNA polymerase (RdRp).
    Patil SM; Maruthi KR; Bajpe SN; Vyshali VM; Sushmitha S; Akhila C; Ramu R
    Bioinformation; 2021; 17(11):932-939. PubMed ID: 35655903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
    Fischer WA; Eron JJ; Holman W; Cohen MS; Fang L; Szewczyk LJ; Sheahan TP; Baric R; Mollan KR; Wolfe CR; Duke ER; Azizad MM; Borroto-Esoda K; Wohl DA; Coombs RW; James Loftis A; Alabanza P; Lipansky F; Painter WP
    Sci Transl Med; 2022 Jan; 14(628):eabl7430. PubMed ID: 34941423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.